StacksVerified U.S. regulatory reference

10 CFR §35.300

Verified against eCFR.gov as of June 20, 2026View official text on eCFR.gov
A licensee may use any unsealed byproduct material identified in § 35.390(b)(1)(ii)(G) prepared for medical use and for which a written directive is required that is—
  1. (a)Obtained from:
    1. (1)A manufacturer or preparer licensed under § 32.72 of this chapter or equivalent Agreement State requirements; or
    2. (2)A PET radioactive drug producer licensed under § 30.32(j) of this chapter or equivalent Agreement State requirements; or
  2. (b)Excluding production of PET radionuclides, prepared by:
    1. (1)An authorized nuclear pharmacist;
    2. (2)A physician who is an authorized user and who meets the requirements specified in §§ 35.290, 35.390, or
    3. (3)An individual under the supervision, as specified in § 35.27, of the authorized nuclear pharmacist in paragraph (b)(1) of this section or the physician who is an authorized user in paragraph (b)(2) of this section; or
  3. (c)Obtained from and prepared by an NRC or Agreement State licensee for use in research in accordance with an Investigational New Drug (IND) protocol accepted by FDA; or
  4. (d)Prepared by the licensee for use in research in accordance with an Investigational New Drug (IND) protocol accepted by FDA.